CareDx, Inc. (NASDAQ:CDNA – Get Free Report) Director Hannah Valantine sold 12,103 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the sale, the director directly owned 36,686 shares in the company, valued at $847,813.46. This represents a 24.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Trading Up 1.0%
Shares of CareDx stock opened at $23.48 on Thursday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -146.75 and a beta of 2.49. CareDx, Inc. has a 1-year low of $10.96 and a 1-year high of $24.85. The firm’s 50-day moving average price is $21.14 and its two-hundred day moving average price is $19.74.
CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.23. The firm had revenue of $117.70 million for the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The company’s quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. As a group, equities research analysts predict that CareDx, Inc. will post 0.22 EPS for the current year.
Institutional Trading of CareDx
Wall Street Analyst Weigh In
CDNA has been the topic of several research analyst reports. BTIG Research upped their price objective on shares of CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Wells Fargo & Company upped their price objective on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CareDx in a research note on Wednesday, May 27th. Finally, Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $25.00.
Read Our Latest Stock Analysis on CDNA
About CareDx
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
See Also
- Five stocks we like better than CareDx
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
